The George Institute For Global Health
Global
United Kingdom
India
China
Australia

George Institute and George Clinical amongst finalists in State Export Awards

Media release: 
19/09/2019

SYDNEY, SEPT 19 - The George Institute and social enterprise arm George Clinical have been listed as Finalists in the 2019 Premier's NSW Export Awards, announced in Sydney last night.

The 2019 Premier's NSW Export Awards is an annual program recognising excellence in the export of goods and services by NSW businesses and their contribution to the economy through job creation and increased prosperity for the community and for the state.

The George Institute was a Finalist in the International Health category and George Clinical in the NSW Exporter to Asia category, reflecting a commitment to the George Institute for Global Health’s mission of improving the health of millions of people worldwide.

Mr Tim Regan, Chief Operating Officer at the George Institute commented,

“We are delighted to be recognised for our contribution to the NSW economy and the health of communities both here and across the globe.”

 

“The George Institute for Global Health was established by Professors Robyn Norton and Stephen MacMahon in Sydney in 1999, with a focus on non-communicable diseases and injuries that was lacking in many research institutes and countries at that time.”

“Since then, the Institute has grown to 700 staff across offices in Australia, China, India and the UK, has conducted research projects in 50 countries, worked with over 1100 collaborators, and raised over $900 million for global health research.”

The Institute, is affiliated with world class universities, including the University of NSW and its researchers have been recognised among the world's best for scientific impact and excellence. In 2017, it celebrated 10 years of operations in China and India. Last year it was recognised as the top independent research organisation in Australia by The Times Higher Education.

George Clinical was formed as a social enterprise of The George Institute to develop profits that would underpin the healthcare research conducted by The George Institute. It provides a full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers located throughout Asia, the USA and Europe.  

Non-communicable diseases, or NCDs, collectively cause over 70% of all deaths worldwide, or 41 million people each year, including 15 million people dying prematurely aged between 30 and 69. Over 85 percent of these premature deaths are in low and middle income countries (LMICs).

"When the Institute was founded, low and middle-income countries were primarily focused on maternal and child health and infectious diseases. Professors Norton and MacMahon could see the NCD crisis was looming and wanted the Institute to focus on both LMICs, and resource-poor individuals and regions within high-income countries," said Mr Regan.

The Institute has been ranked among the top 10 research institutions in the world for scientific impact by the SCImago Institutions Rankings World Report from 2011 to 2014, won the Judges' Vote in the Google Impact Challenge for heart attack text messaging in 2016, and received the AustCham Westpac Australia-China Business Excellence Award for Sustainability, Diversity and Social Responsibility in 2017.

The Premier's NSW Export Award winners from the 13 industry categories automatically progress as national finalists to the Australian Export Awards, they compete for national awards, including the coveted Australian Exporter of the Year.

NSW winners will be announced at a prestigious gala presentation dinner on 16 October 2019 at The Star, Pyrmont, in Sydney.

The George Institute for Global Health

The George Institute for Global Health conducts clinical, population and health system research aimed at changing health practice and policy worldwide. Established in Australia and affiliated with UNSW Sydney, it also has offices in China, India and the UK, and is affiliated with the University of Oxford. 

George Clinical

George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With 20 years of experience and more than 300 people managing 38 geographical locations throughout the USA, Asia-Pacific region and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials. Visit George Clinical website.